



Center for ImmunoMonitoring Nantes Atlantique

Nantes, January 15th, 2008 - The biotechnology company **TcLand Expression SA** and its partners, Nantes' University Hospital, Atlanstat, and Nantes' "GIS Ouest Genopole" transcriptomics platform, today announced the creation of CIMNA, a unique integrated immunomonitoring service platform located in Nantes.

CIMNA will be managed by **TcLand Expression SA** (one of the Atlantic Biotherapies Competitiveness Cluster's leading companies).

With immune response profiling and monitoring being acknowledged key elements in the development of new biotherapies - particularly in the areas of auto-immune disorders, infectious disease, cancer, transplantation, allergies and vaccines, CIMNA's ambition is to become a major European player in immunomonitoring by providing clinical investigators and industrial researchers with access to a high-quality, one-stop shop. By bringing together all the local stakeholders in the field of immunomonitoring, the Center will offer a critical mass of services in an environment meeting industrial standards.

CIMNA involves 4 partners with complementary skills and facilities:

- TcLand Expression SA, the industrial partner, whose Immunomonitoring Services business unit (repertoire analysis, TcLandscape, BcLandscape, qPCR, etc.) will manage the CIMNA.
- Nantes University Hospital's Immunomonitoring Department, which provides a broad range of technology platforms (cytometry, ELISpot, cytokine assays, etc.).
- Atlanstat, a CRO specializing in study monitoring, data management and biostatistics.
- Nantes' "GIS Ouest Genopole" transcriptomics platform, France's leading facility for DNA microarrays.

CIMNA will be backed by a high-level Scientific Advisory Board ensuring best adequation and interpretation of information for the specific needs of its partners.

With pharmaceutical & biotech companies accounting for more than two thirds of CIMNA's customer base, the new Center meets unmet needs in terms of expert analysis, research services, clinical monitoring and innovative technologies, while complying with all the latest quality standards. CIMNA's customers also include academic and public-sector laboratories, to which it provides clinical study monitoring and immunology research services.

CIMNA contacts:

TcLand Expression SA

Incorporated: 2002

Activity: a biotech company specializing in immunomonitoring and the development of gene expression biomarkers in transplantation and auto-immune disorders.

Staff: 25

Web site: www.tcland-expression.com

Sales & business development: Sébastien Brèche, sbreche@tcland-expression.com

Chairman Scientific Advisory Board: Dr Régis Josien, Regis.Josien@univ-nantes.fr

Immunomonitoring: analysis and monitoring of the immune response in patients participating in clinical studies, using validated technologies.

#

This press release may contain forward-looking statements. As such, they do not guarantee future performance; there are risks and uncertainties. Future scientific, preclinical, clinical, regulatory, manufacturing, financial, commercial, business outcomes may be substantially different from those suggested by the forward-looking statements. The forward-looking statements are effective only as per the date at the top of this press release.

Press contacts

Alizé PR Caroline Carmagnol
+33 (0)6 64 18 99 59 caroline@alizerp.com
TcLand Expression SA – ahuriez@tcland-expression.com